)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Vivoryon Therapeutics (VVY) investor relations material
Vivoryon Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary4 Dec, 2025
Executive summary
Presented compelling Phase II data for varoglutamstat, showing significant and consistent improvement in kidney function, especially in patients with more severe impairment and lower baseline eGFR, supporting advancement to a Phase IIb study in diabetic kidney disease (DKD).
Strong interest from the scientific, medical, and biopharma communities, with data presented at ASN Kidney Week and ongoing negotiations with strategic investors.
Completed a €5.1 million private placement, extending cash runway into Q3 2026 and providing flexibility for strategic partnerships.
CFO transition announced, with Marcus Irsfeld (or Ilsfeld) succeeding Anne Doering in December 2025.
Financial highlights
R&D expenses for the first nine months of 2025 were €3.7 million, down from €12.6 million in the same period of 2024, mainly due to lower clinical development and production costs.
G&A expenses decreased to €4.0 million from €4.9 million year-over-year, primarily due to lower personnel costs.
Net loss for the first nine months of 2025 was €7.6 million, compared to €17.1 million in 2024.
Cash and cash equivalents stood at €2.5 million at the end of September 2025, with an additional €5.1 million raised in October via private placement.
No revenue reported for the nine months ended September 30, 2025, and 2024.
Outlook and guidance
Cash runway, including the October 2025 private placement, is expected to fund operations well into Q3 2026.
Plans to advance varoglutamstat into a Phase IIb study in stage 3b/4 DKD, with ongoing preparations including CRO selection and study synopsis development.
Initiation of the Phase IIb DKD study and future studies depends on securing further funding or partnerships.
Actively pursuing additional strategic financing and partnership opportunities.
Continued operating losses are expected, and the ability to continue as a going concern in 2026 depends on raising additional capital.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Vivoryon Therapeutics earnings date
Q4 202524 Apr, 2026
Next Vivoryon Therapeutics earnings date
Q4 202524 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Vivoryon Therapeutics N.V., previously known as Probiodrug, is a Germany-based clinical-stage biopharmaceutical company. It specializes in the discovery and development of therapies for patients suffering from age-related diseases, with a primary focus on Alzheimer’s disease and cancer immune checkpoint inhibition. The company leverages its expertise in understanding post-translational modifications to develop small molecule medications that modulate the activity and stability of proteins altered in disease settings. The company is headquartered in Halle (Saale), Germany, and its shares are listed on the Euronext Amsterdam.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage